Gemzar

(gemcitabine hydrochloride)

Phase 3Small molecule

Gemcitabine is a chemotherapy drug used to treat various types of cancer, including pancreatic cancer, lung cancer, and breast cancer, by slowing or stopping the growth of cancer cells.[1] Gemzar is currently being investigated across 22 indications[3], with its most advanced program in Phase 3.[1]

Gemzar is one of 347 small molecule programs targeting Epstein-Barr virus infection. It is currently in Phase 3.

Indications

480

Total Trials

Active Trials

346

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Epstein-Barr Virus InfectionActive, not recruiting

Gallbladder CancerCompleted

AdenocarcinomaNot yet recruiting

Ovarian CarcinomaUnknown

Liver CancerCompleted

Breast CarcinomaUnknown

Uterine SarcomaActive, not recruiting

Fallopian Tube CancerActive, not recruiting

Pancreatic AdenocarcinomaActive, not recruiting

Pancreatic CancerCompleted

Epstein-Barr Virus InfectionPreclinical

Active, not recruiting

Gallbladder CancerPhase 2

Completed

AdenocarcinomaPreclinical

Not yet recruiting

Ovarian CarcinomaPreclinical

Unknown

Liver CancerPhase 2

Completed

Breast CarcinomaPreclinical

Unknown

Uterine SarcomaPreclinical

Active, not recruiting

Fallopian Tube CancerPhase 3

Active, not recruiting

Pancreatic AdenocarcinomaPhase 2

Active, not recruiting

Pancreatic CancerPhase 3

Completed

Showing 10 of 22 indications

Competition

Competitive Landscape

307 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

Gemzar

Medrol

1 3

Byetta

AstraZeneca

Preclinical

1 4

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

1 5

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 6

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 7

Active Comparator

Moderna

Preclinical

1 8

Sulfonylureas

Eli Lilly

Preclinical

1 9

HS-20093

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Preclinical

1 10

Concurrent Lenvatinib

TTrans Tasman Radiation Oncology Group

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 3Recruiting

Chemotherapy

NCT05342194

Q1 2030

Phase 2Recruiting

Refractory Solid Tumors

NCT05733000

Q1 2031

Phase 3Recruiting

Breast Cancer

NCT06255392

Clinical

Trials by Indication[1]

Pancreatic Cancer44 trials

Gemcitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Completed·EEastern Cooperative Oncology Group·Phase 3·NCT00058149

S0727 Gemcitabine Hydrochloride and Erlotinib Hydrochloride With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery

Completed·NNational Cancer Institute (NCI)·Phase 1/2·NCT00617708·134 enrolled

Radiotherapy Combined With Oxaliplatin and Fluorouracil Followed By Gemcitabine in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00096070·50 enrolled

Show 41 more trials

Gemcitabine and Oxaliplatin in Treating Patients With Metastatic Pancreatic Cancer

Unknown status·GGERCOR - Multidisciplinary Oncology Cooperative Group·Phase 3·NCT00268411·80 enrolled

Flavopiridol Plus Radiation Therapy Followed By Gemcitabine Hydrochloride in Treating Patients With Locally Advanced, Unresectable Pancreatic Cancer

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00047307·46 enrolled

Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Pancreatic Cancer

Completed·UUNICANCER·Phase 2/3·NCT00112658·342 enrolled

Gemcitabine With or Without Sorafenib in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Unknown status·IInstitut Paoli-Calmettes·Phase 3·NCT00541021·104 enrolled

Chemotherapy and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00049348

Docetaxel and Gemcitabine Compared With Docetaxel and Cisplatin in Treating Patients With Metastatic or Locally Advanced Pancreatic Cancer

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00004884·96 enrolled

Gemcitabine, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery

Completed·LLisette Nixon·Phase 2·NCT01032057·114 enrolled

Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Metastatic or Unresectable Pancreatic Cancer

Completed·RRoswell Park Cancer Institute·Phase 2·NCT00100815·50 enrolled

Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Pancreatic Cancer That Can Be Removed By Surgery

Withdrawn·RRoswell Park Cancer Institute·N/A·NCT00524069

Dasatinib and Gemcitabine Hydrochloride or Gemcitabine Hydrochloride Alone in Treating Patients With Pancreatic Cancer Previously Treated With Surgery

Completed·TTranslational Oncology Research International·Phase 2·NCT01234935·8 enrolled

3-AP and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer

Completed·VVion Pharmaceuticals·Phase 2·NCT00064051

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Unresectable Pancreatic Cancer

Completed·WWake Forest University Health Sciences·Phase 2·NCT00025168·20 enrolled

Gemcitabine With/Out Erlotinib in Unresectable Locally Advanced/Metastatic Pancreatic Cancer

Completed·NNCIC Clinical Trials Group·Phase 3·NCT00026338·569 enrolled

Gemcitabine Compared With Pancreatic Enzyme Therapy Plus Specialized Diet (Gonzalez Regimen) in Treating Patients Who Have Stage II, Stage III, or Stage IV Pancreatic Cancer

Terminated·—·N/A·NCT00003851·90 enrolled

Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer

Withdrawn·NNational Cancer Institute (NCI)·Phase 2·NCT00253526

Stereotactic Radiation Therapy and Combination Chemotherapy in Treating Patients Undergoing Surgery for Locally Advanced Pancreatic Cancer

Completed·TTechnical University of Munich·Phase 2·NCT00425841·29 enrolled

Gemcitabine Plus Oxaliplatin in Treating Patients With Refractory Locally Advanced or Metastatic Pancreatic Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00004190·59 enrolled

Gemcitabine, Nab-paclitaxel and KPT-330 in Advanced Pancreatic Cancer

Completed·MMohammed Najeeb Al Hallak·Phase 1/2·NCT02178436·15 enrolled

Gemcitabine With or Without Capecitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Completed·CCancer Research UK·Phase 3·NCT00032175·508 enrolled

Gemcitabine With or Without Dalteparin in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Completed·HHull University Teaching Hospitals NHS Trust·Phase 2·NCT00462852·120 enrolled

Sorafenib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00114244·52 enrolled

Sunitinib and Gemcitabine in Treating Patients With Pancreatic Cancer or Other Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00462553·37 enrolled

Conatumumab, Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Pancreatic Cancer

Withdrawn· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 1/2·NCT01017822

Bevacizumab, Combination Chemotherapy, and Radiation Therapy in Treating Patients Undergoing Surgery For Locally Advanced Pancreatic Cancer

Completed·—·Phase 2·NCT00602602·19 enrolled

Gemcitabine With or Without CI-994 in Treating Patients With Advanced Pancreatic Cancer

Completed· Pfizer logo

Pfizer·Phase 2·NCT00004861

Combination Chemotherapy Followed by Chemotherapy and Radiation Therapy and/or Surgery in Treating Patients Who Have Pancreatic Cancer

Completed·NNYU Langone Health·Phase 1/2·NCT00003332·36 enrolled

Bortezomib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00052689·88 enrolled

Gemcitabine Hydrochloride in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery

Completed·FFederation Francophone de Cancerologie Digestive·Phase 2·NCT01416662·120 enrolled

Gemcitabine and Celecoxib in Treating Patients With Metastatic Pancreatic Cancer

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00068432·28 enrolled

AZD0530 and Gemcitabine in Locally Advanced/Metastatic Pancreatic Cancer That Cannot Be Removed By Surgery

Completed·NNCIC Clinical Trials Group·Phase 1/2·NCT00265876·34 enrolled

Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable Pancreatic Cancer

Terminated·—·Phase 2·NCT01897454·23 enrolled

Ceritinib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors or Locally Advanced or Metastatic Pancreatic Cancer

Completed·RRoswell Park Cancer Institute·Phase 1·NCT02227940·38 enrolled

Gemcitabine With or Without Combination Chemotherapy and Radiation Therapy in Treating Patients With Nonmetastatic Pancreatic Cancer That Cannot Be Removed By Surgery

Completed·FFederation Francophone de Cancerologie Digestive·Phase 3·NCT00416507·190 enrolled

Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT00088894·590 enrolled

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Pancreatic Cancer That Cannot Be Removed by Surgery

Completed·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT00004003·30 enrolled

Triacetyluridine and Fluorouracil Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced, or Metastatic Pancreatic Cancer

Completed·WWellstat Therapeutics·Phase 3·NCT00024427·250 enrolled

Cisplatin, Metronomic Low-Dose Interferon Alfa, Gemcitabine, and Fever-Range Whole-Body Hyperthermia in Treating Patients With Inoperable or Metastatic Pancreatic Cancer

Unknown status·TThe University of Texas Health Science Center, Houston·Phase 2·NCT00082862·48 enrolled

Gemcitabine, Cisplatin, and Radiation Therapy Followed By Surgery or Surgery Alone in Treating Patients With Localized Pancreatic Cancer That Can Be Removed By Surgery

Completed·IInterdisziplinare Arbeitsgruppe Gastrointestinaler Tumore der Deutschen Krebsgesellschaft·Phase 2·NCT00335543·254 enrolled

Sonoporation and Chemotherapy for the Treatment of Pancreatic Cancer

Active, not recruiting·FFlemming Forsberg·Phase 1/2·NCT04821284·120 enrolled

Two Chemotherapy Regimens Compared With Observation in Treating Patients With Completely Resected Pancreatic Cancer

Completed·RRoyal Liverpool University Hospital·Phase 3·NCT00058201·1,030 enrolled

3-AP and Gemcitabine in Treating Patients With Recurrent, Unresectable, or Metastatic Pancreatic Cancer

Completed·UUniversity Health Network, Toronto·Phase 2·NCT00078975·26 enrolled

Non-Small Cell Lung Cancer36 trials

Combination Chemotherapy and Computer-Planned Radiation Therapy in Treating Patients With Unresectable Stage III Non-Small Cell Lung Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00033553·69 enrolled

Chemotherapy and Radiation Therapy With or Without Efaproxiral in Treating Patients With Stage III Non-Small Cell Lung Cancer

Withdrawn· Spectrum Pharmaceuticals, Inc logo

Spectrum Pharmaceuticals, Inc·Phase 3·NCT00055887

Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer

Terminated·AAlliance for Clinical Trials in Oncology·Phase 3·NCT01041781·313 enrolled

Show 33 more trials

Surgery With or Without Preoperative Chemotherapy in Treating Patients With Resectable Non-small Cell Lung Cancer

Completed·MMedical Research Council·Phase 3·NCT00003159·600 enrolled

Prinomastat and Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Non-small Cell Lung Cancer

Completed· Pfizer logo

Pfizer·Phase 3·NCT00004199

FDG-Labeled PET Scan in Planning Chemotherapy in Treating Patients With Stage IIIB or IV Non-Small Cell Lung Cancer

Completed·UUniversity of Washington·Phase 2·NCT00564733·55 enrolled

Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00041314

Enzastaurin, Carboplatin, and Gemcitabine With or Without Bevacizumab in Treating Patients With Recurrent, Stage IIIB, or Stage IV Non-Small Cell Lung Cancer

Withdrawn·EEastern Cooperative Oncology Group·Phase 2·NCT00469976

Gemcitabine and Carboplatin Followed by Paclitaxel in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT00276588·46 enrolled

Gemcitabine With or Without CI-994 in Treating Patients With Advanced Non-small Cell Lung Cancer

Completed· Pfizer logo

Pfizer·Phase 3·NCT00005093

Irinotecan and Gemcitabine in Treating Patients With Recurrent or Progressive Stage III or Stage IV Non-Small Cell Lung Cancer

Completed·RRoswell Park Cancer Institute·Phase 2·NCT00182806·38 enrolled

Gemcitabine Plus Paclitaxel in Treating Patients With Advanced Non-small Cell Lung Cancer or Other Solid Tumor

Terminated·UUniversity of Alabama at Birmingham·Phase 1/2·NCT00004159·54 enrolled

Gefitinib as First-Line Therapy Followed by Gemcitabine and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Completed·SSwiss Cancer Institute·Phase 2·NCT00217698·63 enrolled

Combination Chemotherapy as Induction Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT00003037

Gemcitabine and Docetaxel in Treating Patients With Inoperable Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Unknown status·GGERCOR - Multidisciplinary Oncology Cooperative Group·Phase 2·NCT00075517

Gemcitabine, Cisplatin, and Gefitinib in Treating Patients Who Are Undergoing Surgery for Stage III Non-Small Cell Lung Cancer

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00103051

Neoadjuvant Chemoradiotherapy With or Without Gefitinib in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer

Completed·UUniversity of Alabama at Birmingham·Phase 1/2·NCT00062270

Polyglutamate Paclitaxel Compared With Gemcitabine or Vinorelbine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

Terminated·CCTI BioPharma·Phase 3·NCT00054197

Gemcitabine Plus Radiation Therapy or Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer

Completed·WWake Forest University Health Sciences·Phase 1/2·NCT00003202·40 enrolled

AZD2171 and Standard Combination Chemotherapy in Advanced Non-Small Cell Lung Cancer or Colorectal Cancer

Completed·NNCIC Clinical Trials Group·Phase 1·NCT00343408·31 enrolled

Genetic Changes in Patients With Non-Small Cell Lung Cancer Who Are Receiving Vinorelbine and Gemcitabine Before Surgery

Completed·RRoswell Park Cancer Institute·Phase 2·NCT00057798·21 enrolled

3-AP and Gemcitabine as Second-Line Therapy in Treating Patients With Stage III or Stage IV Recurrent Non-Small Cell Lung Cancer

Completed·CCancer Therapeutics Research Group·Phase 2·NCT00077415·31 enrolled

Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer

Terminated·SSidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University·Phase 2·NCT03366766·14 enrolled

Combination Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00003589·450 enrolled

Pemetrexed Disodium, Gemcitabine, and Bevacizumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Terminated·BBarbara Ann Karmanos Cancer Institute·Phase 2·NCT00438204·39 enrolled

Vinorelbine and/or Gemcitabine in Treating Older Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer

Unknown status·IIstituto Nazionale per lo Studio e la Cura dei Tumori·Phase 3·NCT00003447·630 enrolled

Fludeoxyglucose F-18 PET/CT in Predicting Response to Chemotherapy in Patients With Stage IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery

Withdrawn·EECOG-ACRIN Cancer Research Group·Phase 2·NCT02607423

Hospitalization Rates of Patients With Non-Small Cell Lung Cancer Treated With Gemcitabine and Either Cisplatin or Carboplatin

Unknown status·TThe Christie NHS Foundation Trust·Phase 3·NCT00055965·400 enrolled

Gemcitabine and Carboplatin With or Without AZD2171 as First-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00326599·101 enrolled

Combination Chemotherapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer

Withdrawn·FFox Chase Cancer Center·Phase 3·NCT00054392

Chemotherapy Plus Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Cannot Be Surgically Removed

Terminated·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00003803·158 enrolled

Tipifarnib, Gemcitabine, and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00055757·48 enrolled

Combination Chemotherapy Plus Fluoxetine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00005850·21 enrolled

Gemcitabine and Docetaxel in Treating Patients With Recurrent Stage III or Stage IV Non-Small Cell Lung Cancer

Completed·WWake Forest University Health Sciences·Phase 2·NCT00278460·49 enrolled

Vinorelbine, Gemcitabine, and Docetaxel Compared With Paclitaxel and Carboplatin in Treating Patients With Advanced Non-Small Cell Lung Cancer

Completed·JJapan Multinational Trial Organization·Phase 3·NCT00079287

Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT01443078·42 enrolled

Patients With Advanced Solid Tumors9 trials

Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors

Completed·MMasonic Cancer Center, University of Minnesota·Phase 1·NCT00620295·17 enrolled

Gemcitabine Plus Flavopiridol in Treating Patients With Advanced Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00007917·58 enrolled

Combination Chemotherapy in Treating Patients With Advanced Solid Tumors

Completed·—·Phase 1·NCT00006372·10 enrolled

Show 6 more trials

Gamma-Secretase Inhibitor RO4929097 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT01145456·18 enrolled

Tanespimycin, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00047047·78 enrolled

BMS-247550 and Gemcitabine in Treating Patients With Advanced Solid Tumors

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT00043095

Gemcitabine Combined With Mistletoe in Treating Patients With Advanced Solid Tumors

Terminated·NNational Center for Complementary and Integrative Health (NCCIH)·Phase 1·NCT00049608·51 enrolled

Gemcitabine Hydrochloride and Smac Mimetic TL32711 in Treating Patients With Advanced Solid Tumors

Terminated·RRoswell Park Cancer Institute·Phase 1·NCT01573780·21 enrolled

Carboplatin and Gemcitabine in Treating Patients With Advanced Solid Tumors

Completed·FFox Chase Cancer Center·Phase 1·NCT00021346·8 enrolled

Lymphoma8 trials

Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone With or Without Gemcitabine in Treating Patients With Previously Untreated Aggressive Non-Hodgkin's Lymphoma

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT00079261·25 enrolled

Combination Chemotherapy in Hodgkin's Disease or Non-Hodgkin's Lymphoma Not Responding to Previous Treatment

Completed·NNCIC Clinical Trials Group·Phase 2·NCT00014209·77 enrolled

Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma

Completed·AAlliance for Clinical Trials in Oncology·Phase 1/2·NCT00006029·91 enrolled

Show 5 more trials

Combination Chemotherapy in Treating Patients With Recurrent, Refractory, or Metastatic Solid Tumors or Lymphomas

Completed·NNational Institutes of Health Clinical Center (CC)·Phase 1·NCT00019513·108 enrolled

AMG 706 and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma

Unknown status·JJonsson Comprehensive Cancer Center·Phase 1·NCT00324597·18 enrolled

Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

Completed·NNCIC Clinical Trials Group·Phase 3·NCT00078949·849 enrolled

Gemcitabine, Cisplatin, and Dexamethasone in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma

Completed·JJonsson Comprehensive Cancer Center·Phase 2·NCT00090909·1 enrolled

Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma

Completed·UUniversity of Maryland, Baltimore·Phase 2·NCT00003397·25 enrolled

Bladder Cancer7 trials

Combination Chemotherapy in Treating Patients With Bladder Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 3·NCT00014534·42 enrolled

Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Bladder Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1/2·NCT00003105·30 enrolled

Cisplatin and Gemcitabine Compared With Observation in Treating Patients Who Have Undergone Surgery for Bladder Cancer

Unknown status·FFondazione C.N.R./Regione Toscana "G. Monasterio", Pisa, Italy·Phase 3·NCT00054626·700 enrolled

Show 4 more trials

Gemcitabine, Cisplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Bladder Cancer

Completed·IInstitut du Cancer de Montpellier - Val d'Aurelle·Phase 1/2·NCT00556621·14 enrolled

Gemcitabine With Or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Bladder Cancer

Completed·IInstitut du Cancer de Montpellier - Val d'Aurelle·Phase 2·NCT00627432·44 enrolled

Gemcitabine, Cisplatin, and Amifostine Following Surgery in Treating Patients With Locally Advanced Bladder Cancer

Completed·UUniversity of Chicago·Phase 2·NCT00006105·37 enrolled

Combination Chemotherapy in Treating Patients With Stage IV Locally Advanced or Metastatic Bladder Cancer

Completed·UUniversity of Chicago·Phase 2·NCT00005086·6 enrolled

58 more indications

Advanced Cancer6 trials

Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney Function

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00005644

Oxaliplatin and Gemcitabine in Treating Patients With Advanced Cancer

Completed·—·Phase 1·NCT00004220

Combination Chemotherapy in Treating Patients With Advanced Cancer

Completed·TThe University of Texas Health Science Center at San Antonio·Phase 1·NCT00003707·22 enrolled

Show 3 more trials

Cisplatin, Gemcitabine, Interferon Alfa, and Hyperthermia in Treating Patients With Advanced Cancer

Unknown status·TThe University of Texas Health Science Center, Houston·Phase 1/2·NCT00004063·30 enrolled

Gemcitabine, Paclitaxel, and Cisplatin in Treating Patients With Advanced Cancer of the Urothelium

Completed·WWake Forest University Health Sciences·Phase 2·NCT00310011·71 enrolled

Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00053209·46 enrolled

Breast Cancer6 trials

Liposomal Doxorubicin and Gemcitabine in Treating Women With Metastatic Breast Cancer

Unknown status·PPharmatech Oncology·Phase 2·NCT00027989

Carboplatin and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Breast Cancer

Terminated·UUniversity of Southampton·Phase 2·NCT00470249·5 enrolled

Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer

Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 3·NCT06255392·200 enrolled

Show 3 more trials

Gemcitabine in Treating Women With Metastatic Breast Cancer Previously Treated With Doxorubicin and Paclitaxel

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00003540·30 enrolled

Gemcitabine +/- Imatinib Mesylate, Patients w/Previously Treated Metastatic Breast Cancer

Terminated·RRutgers, The State University of New Jersey·Phase 2·NCT00323063·49 enrolled

Gemcitabine and Liposomal Doxorubicin in Treating Women With Metastatic Breast Cancer

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00005991·76 enrolled

Fallopian Tube Cancer5 trials

Combination Chemotherapy Consisting of Gemcitabine And Topotecan in Treating Patients With Refractory or Recurrent Ovarian or Fallopian Tube Cancer

Terminated·GGynecologic Oncology Group·Phase 1·NCT00003382

Liposome-Encapsulated Doxorubicin Citrate With or Without Gemcitabine Hydrochloride in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer

Unknown status·MMedical University Innsbruck·Phase 2·NCT01100372·154 enrolled

Gemcitabine and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer That Responded to Previous Cisplatin or Carboplatin

Withdrawn·GGynecologic Oncology Group·Phase 2·NCT00369954

Show 2 more trials

Two Different Schedules of Carboplatin, Paclitaxel, Gemcitabine, and Surgery in Treating Patients With Newly Diagnosed Stage IIIC or Stage IV Primary Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Unknown status·WWarwick Medical School·Phase 2·NCT00838656·88 enrolled

Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Completed·MMayo Clinic·Phase 2·NCT02312245·13 enrolled

Cholangiocarcinoma4 trials

S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or Cholangiocarcinoma

Completed·SSWOG Cancer Research Network·Phase 2·NCT00033540·57 enrolled

Sirolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients At High Risk for Cholangiocarcinoma Recurrence After Liver Transplant or Surgery

Completed·MMayo Clinic·Phase 1·NCT01888302·1 enrolled

Gemcitabine and Capecitabine in Treating Patients With Advanced and/or Inoperable Cholangiocarcinoma or Carcinoma of the Gallbladder

Completed·RRoswell Park Cancer Institute·Phase 2·NCT00084942

Show 1 more trial

S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct

Completed·SSWOG Cancer Research Network·Phase 2·NCT00789958·105 enrolled

Cancer of the Pancreas4 trials

Gemcitabine and Monoclonal Antibody Therapy in Treating Patients With Metastatic Cancer of the Pancreas

Unknown status·—·Phase 2·NCT00003797·41 enrolled

Chemotherapy Compared to Biological Therapy in Treating Patients With Cancer of the Pancreas

Unknown status·UUnknown Sponsor·Phase 2·NCT00003780·150 enrolled

Fluorouracil, Gemcitabine, and Radiation Therapy in Treating Patients With Cancer of the Pancreas

Completed· Radiation Therapy Oncology Group logo

Radiation Therapy Oncology Group·Phase 3·NCT00003216·518 enrolled

Show 1 more trial

Cetuximab Plus Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or Recurrent Cancer of the Pancreas

Withdrawn·UUniversity of Alabama at Birmingham·Phase 2·NCT00005591

Kidney Cancer4 trials

Gemcitabine and Irinotecan in Treating Patients With Metastatic Kidney Cancer

Completed·TThe Cleveland Clinic·Phase 2·NCT00401128·9 enrolled

Combination Chemotherapy and Biological Therapy In Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed Surgically

Unknown status·CCancer Biotherapy Research Group·Phase 2·NCT00003664·30 enrolled

Gemcitabine Plus Cisplatin in Treating Patients With Metastatic Kidney Cancer

Completed·—·Phase 2·NCT00003928·32 enrolled

Show 1 more trial

Combination Chemotherapy in Treating Patients With Advanced Bladder or Kidney Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT00003342·30 enrolled

Locally Advanced3 trials

Gemcitabine With/Out Capecitabine in Locally Advanced, Unresectable, or Metastatic Biliary Cancer

Terminated·NNCIC Clinical Trials Group·Phase 3·NCT00658593·19 enrolled

Cisplatin or Carboplatin Combined With Gemcitabine in Locally Advanced, Recurrent, or Metastatic Malignant Salivary Gland Tumor

Completed·NNCIC Clinical Trials Group·Phase 2·NCT00079079·34 enrolled

Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the Urothelium

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT00080795·65 enrolled

Primary Peritoneal Cancer3 trials

Cisplatin and Gemcitabine in Treating Patients With Refractory or Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT00003358·24 enrolled

Gemcitabine Plus Cisplatin in Treating Patients With Ovarian Epithelial Cancer or Primary Peritoneal Cancer That Is Recurrent or Has Not Responded to Platinum-based Chemotherapy

Completed·GGynecologic Oncology Group·Phase 2·NCT00006028

Combination Chemotherapy in Treating Patients With Previously Untreated Stage III or Stage IV Ovarian or Primary Peritoneal Cancer

Terminated·GGynecologic Oncology Group·Phase 1·NCT00003378·45 enrolled

Chemotherapy3 trials

Combination Chemotherapy Plus Filgrastim in Treating Patients With Locally Recurrent or Advanced Urothelium Cancer

Unknown status· Amgen logo

Amgen·Phase 2·NCT00005958

Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study

Recruiting·SShanghai Junshi Bioscience Co., Ltd.·Phase 3·NCT05342194·480 enrolled

Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix

Completed·GGynecologic Oncology Group·Phase 3·NCT00064077·513 enrolled

Biliary Tract Cancer2 trials

Fluorouracil, Cisplatin, and Radiation Therapy or Gemcitabine and Oxaliplatin in Treating Patients With Nonmetastatic Biliary Tract Cancer That Cannot Be Removed By Surgery

Completed·FFederation Francophone de Cancerologie Digestive·Phase 2/3·NCT00304135·34 enrolled

Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract Cancers

Completed·SSWOG Cancer Research Network·Phase 3·NCT03768414·452 enrolled

Small Cell Lung Cancer2 trials

S0119: Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Completed·SSWOG Cancer Research Network·Phase 2·NCT00030433·85 enrolled

Combination Chemotherapy in Treating Patients With Recurrent or Refractory Small Cell Lung Cancer

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00005972·73 enrolled

Peritoneal Cancer2 trials

MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer

Terminated·MMayo Clinic·Phase 2·NCT02364713·17 enrolled

Combination Chemotherapy in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cancer

Completed·AAGO Study Group·Phase 2·NCT00031954·105 enrolled

Multiple Myeloma2 trials

Peripheral Stem Cell Transplantation Plus Combination Chemotherapy in Treating Patients With Multiple Myeloma

Completed·UUniversity of Maryland, Baltimore·Phase 2·NCT00003401

Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT02506959·83 enrolled

Metastatic Urothelial Cancer2 trials

Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT02567409·87 enrolled

Lapatinib, Cisplatin, Gemcitabine as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urothelial Cancer

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 1·NCT00623064·18 enrolled

Liver Cancer2 trials

SCH 66336 With or Without Gemcitabine Followed by Surgery Compared With Surgery Alone in Treating Patients With Primary Liver Cancer

Withdrawn·JJonsson Comprehensive Cancer Center·Phase 2·NCT00020774

Sorafenib With or Without Gemcitabine and Oxaliplatin in Treating Patients With Locally Advanced, Unresectable, or Metastatic Liver Cancer

Completed·IInstitut du Cancer de Montpellier - Val d'Aurelle·Phase 2·NCT00941967·78 enrolled

Gemcitabine2 trials

Cisplatin, Gemcitabine Hydrochloride, and Sorafenib Tosylate in Treating Patients With Transitional Cell Cancer of the Bladder

Unknown status·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano·Phase 2·NCT01222676·45 enrolled

Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00093496·29 enrolled

Urinary Tract Cancer2 trials

Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer

Completed·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00022191·608 enrolled

Combination Chemotherapy Following Surgery in Treating Patients With Urinary Tract Cancer

Completed·TTulane University Health Sciences Center·Phase 2·NCT00028860

Recurrent or Refractory2 trials

Gemcitabine in Treating Patients With Recurrent or Refractory Cancer of the Uterus

Terminated·GGynecologic Oncology Group·Phase 2·NCT00003316

Nitrocamptothecin Compared With Other Chemotherapy in Treating Patients With Recurrent or Refractory Cancer of the Pancreas

Unknown status·AAstex Pharmaceuticals, Inc.·Phase 3·NCT00005870

Chondrosarcoma1 trial

Gemcitabine and Docetaxel in Treating Patients With Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing's Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma

Completed·SSarcoma Alliance for Research through Collaboration·Phase 2·NCT00073983·54 enrolled

Unresectable Solid Tumor1 trial

Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00004242·30 enrolled

Refractory Solid Tumors1 trial

CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors

Recruiting·NNorthwestern University·Phase 2·NCT05733000·94 enrolled

Radiation Therapy1 trial

S0121, Neoadjuvant Carboplatin, Paclitaxel, and Gemcitabine Followed by Cisplatin and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Carcinoma of the Urothelium

Completed·SSWOG Cancer Research Network·Phase 2·NCT00055835·7 enrolled

Breast1 trial

Chemotherapeutic Agents in Brain/Breast

Completed·—··NCT00795678·10 enrolled

Colorectal Cancer1 trial

Gemcitabine, Capecitabine, and Oxaliplatin as Second-Line Therapy in Treating Patients With Advanced Colorectal Cancer Previously Treated With Irinotecan

Unknown status·YYonsei University·Phase 1/2·NCT00496704·56 enrolled

Biliary Cancer1 trial

Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers

Completed·MM.D. Anderson Cancer Center·Phase 2·NCT02392637·62 enrolled

Recurrent Head and Neck Cancer1 trial

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced and/or Recurrent Head and Neck Cancer

Unknown status·NNational Cancer Institute (NCI)·Phase 1·NCT00004097

Metastatic Colorectal Cancer1 trial

Combination Chemotherapy in Treating Patients With Recurrent or Metastatic Colorectal Cancer

Unknown status·SStony Brook University·Phase 1/2·NCT00003001·63 enrolled

Solid Tumors1 trial

Gemcitabine and Cisplatin in Treating Patients With Metastatic or Recurrent Solid Tumors

Completed·NNorthwestern University·Phase 1·NCT00004090

Chronic Myelogenous Leukemia1 trial

Chemotherapy and Peripheral Stem Cell Transplantation Followed by Immunotherapy in Treating Patients With Chronic Myelogenous Leukemia

Completed·UUniversity of Maryland, Baltimore·Phase 2·NCT00003727·22 enrolled

Metastatic Solid Tumors1 trial

Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors

Completed·NNorthwestern University·Phase 1·NCT00004095·38 enrolled

Chronic Lymphocytic Leukemia1 trial

Gemcitabine in Treating Patients With Recurrent Chronic Lymphocytic Leukemia

Completed·AAlliance for Clinical Trials in Oncology·Phase 2·NCT00005829·22 enrolled

Mesothelioma1 trial

Combination Chemotherapy Before Surgery in Treating Patients With Mesothelioma of the Lung

Completed·SSwiss Cancer Institute·Phase 2·NCT00030745·61 enrolled

Uterine Leiomyosarcoma1 trial

Docetaxel, Gemcitabine, and Filgrastim (G-CSF) or Pegfilgrastim in Treating Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcoma

Completed·GGynecologic Oncology Group·Phase 2·NCT00101127

Nasopharyngeal Cancer1 trial

Gemcitabine and Carboplatin Followed By Laboratory-Treated T Lymphocytes in Treating Patients With Metastatic or Locally Recurrent Epstein-Barr Virus-Positive Nasopharyngeal Cancer

Unknown status·NNational Cancer Centre, Singapore·Phase 2·NCT00690872·35 enrolled

Squamous Cell Cancer of the Head and Neck1 trial

Cisplatin and Gemcitabine in Treating Patients With Advanced Squamous Cell Cancer of the Head and Neck

Unknown status·HHope Cancer Institute, Inc.·Phase 1/2·NCT00003182·40 enrolled

Advanced Solid Tumors1 trial

Irinotecan and Gemcitabine in Treating Patients With Refractory Advanced Solid Tumors

Completed·RRoswell Park Cancer Institute·Phase 1·NCT00054288

Urothelial Cancer1 trial

Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer

Withdrawn·UUniversity of Southern California·Phase 2·NCT01639521

Cervical Cancer1 trial

S0227 Cisplatin With Either Paclitaxel or Gemcitabine in Recurrent, Persistent, or Metastatic Cervical Cancer

Withdrawn·SSWOG Cancer Research Network·Phase 3·NCT00057928

Recurrent Cancer1 trial

Gemcitabine and Cisplatin in Treating Patients With Refractory or Recurrent Cancer of the Cervix

Terminated·GGynecologic Oncology Group·Phase 2·NCT00006482

First Line Therapy1 trial

Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium

Completed·—·Phase 1/2·NCT01090466·15 enrolled

Cancer of Unknown Primary1 trial

Gemcitabine, Docetaxel, and Capecitabine in Treating Patients With Cancer of Unknown Primary Origin

Withdrawn·UUniversity of Medicine and Dentistry of New Jersey·Phase 2·NCT00119314

Patients With Solid Tumors1 trial

PR-104 and Docetaxel or Gemcitabine in Treating Patients With Solid Tumors

Completed·PProacta, Incorporated·Phase 1·NCT00459836·42 enrolled

Pancreatic Adenocarcinoma1 trial

Gemcitabine With or Without Oxaliplatin in Treating Patients With Locally Advanced or Metastatic Unresectable Pancreatic Adenocarcinoma

Unknown status·GGERCOR - Multidisciplinary Oncology Cooperative Group·Phase 3·NCT00075452

Adenocarcinoma1 trial

Fluorouracil, External-Beam Radiation Therapy, and Gemcitabine With or Without Brachytherapy Using Phosphorus P32 in Treating Patients With Locally or Regionally Advanced Unresectable Adenocarcinoma of the Pancreas

Unknown status·UUniversity of South Florida·N/A·NCT00079365

Metastatic Colon Cancer1 trial

Gemcitabine and Oxaliplatin as Second-Line Therapy in Treating Patients With Metastatic Colon Cancer

Terminated·UUniversity of Miami·Phase 2·NCT00276861·10 enrolled

T-cell non-Hodgkin lymphoma1 trial

Gemcitabine and Bexarotene in Treating Patients With Progressive or Refractory Stage IB, Stage II, Stage III, or Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma

Completed·UUniversity College, London·Phase 2·NCT00660231·36 enrolled

Transitional Cell Carcinoma1 trial

Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT)

Completed·—·Phase 2·NCT01089088·63 enrolled

Triple-Negative Breast Cancer1 trial

A Trial Evaluating the Efficacy and Safety of EndoTAG®-1 in Combination With Paclitaxel and Gemcitabine Compared With Paclitaxel and Gemcitabine as First-line Therapy in Patients With Visceral Metastatic Triple-negative Breast Cancer

Suspended·SSynCore Biotechnology Co., Ltd.·Phase 3·NCT03002103·420 enrolled

Malignant Mesothelioma1 trial

S9810: Gemcitabine Plus Cisplatin in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot Be Removed by Surgery

Completed·SSWOG Cancer Research Network·Phase 2·NCT00003723·57 enrolled

Acute Lymphoblastic Leukemia1 trial

Gemcitabine in Treating Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous Leukemia

Completed·CChildren's Oncology Group·Phase 2·NCT00006462·32 enrolled

Relapsed or Refractory1 trial

Gemcitabine and Docetaxel in Treating Patients With Relapsed or Refractory Ovarian Epithelial or Peritoneal Cancer

Completed·RRobert Morris·Phase 2·NCT00227721·30 enrolled

Epithelial Tumor1 trial

Combination Chemotherapy in Treating Patients With Previously Untreated, Newly Diagnosed Epithelial Tumors

Completed·—·Phase 1·NCT00004082

Ovarian Cancer1 trial

Sorafenib Tosylate and Gemcitabine Hydrochloride in Treating Patients With Recurrent Epithelial Ovarian Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00096395·33 enrolled

Soft Tissue Sarcoma1 trial

Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00004066·82 enrolled

Stage IV Ovarian Epithelial Cancer1 trial

Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal Cancer

Completed·GGynecologic Oncology Group·Phase 3·NCT00011986·4,312 enrolled

Squamous Cell Cancer1 trial

Radiation Therapy, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Locally Advanced Squamous Cell Cancer of the Vulva

Unknown status·GGynecologic Oncology Group·Phase 2·NCT01595061·57 enrolled

Lymphoid Malignancies1 trial

Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies

Completed·FFred Hutchinson Cancer Center·Phase 2·NCT00072514·55 enrolled

HER2-Positive Solid Tumor1 trial

Trastuzumab Biosimilar (Samfenet®) Plus Treatment of Physician's Choice (TPC) in Patients With HER2-positive Solid Tumor

Unknown status·JJin-Hee Ahn·Phase 2·NCT04215159·42 enrolled

Regulatory

FDA Approval Timeline[4]

May 15, 1996

GEMZAR

NDA NDA020509

Aug 4, 2011

GEMCITABINE HYDROCHLORIDE

NDA NDA200795

Aug 3, 2017

GEMCITABINE HYDROCHLORIDE

NDA NDA209604

Jul 16, 2018

INFUGEM

NDA NDA208313

Jun 27, 2025

AVGEMSI

NDA NDA219920

Sep 9, 2025

INLEXZO

NDA NDA219683

Sources

References

[1]
ClinicalTrials.gov — 480 trial records for gemcitabine hydrochloride. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — gemcitabine hydrochloride compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for gemcitabine hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA219683). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: DNA Polymerase (alpha/delta/epsilon) Inhibitor; Ribonucleoside-Diphosphate Reductase RR1 Inhibitor[2]
Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Johnson & Johnson

Gemzar

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q1 2030

Q1 2031

Trials by Indication[1]

Pancreatic Cancer44 trials

Non-Small Cell Lung Cancer36 trials

Patients With Advanced Solid Tumors9 trials

Lymphoma8 trials

Bladder Cancer7 trials

Advanced Cancer6 trials

Breast Cancer6 trials

Fallopian Tube Cancer5 trials

Cholangiocarcinoma4 trials

Cancer of the Pancreas4 trials

Kidney Cancer4 trials

Locally Advanced3 trials

Primary Peritoneal Cancer3 trials

Chemotherapy3 trials

Biliary Tract Cancer2 trials

Small Cell Lung Cancer2 trials

Peritoneal Cancer2 trials

Multiple Myeloma2 trials

Metastatic Urothelial Cancer2 trials

Liver Cancer2 trials

Gemcitabine2 trials

Urinary Tract Cancer2 trials

Recurrent or Refractory2 trials

Chondrosarcoma1 trial

Unresectable Solid Tumor1 trial

Refractory Solid Tumors1 trial

Radiation Therapy1 trial

Breast1 trial

Colorectal Cancer1 trial

Biliary Cancer1 trial

Recurrent Head and Neck Cancer1 trial

Metastatic Colorectal Cancer1 trial

Solid Tumors1 trial

Chronic Myelogenous Leukemia1 trial

Metastatic Solid Tumors1 trial

Chronic Lymphocytic Leukemia1 trial

Mesothelioma1 trial

Uterine Leiomyosarcoma1 trial

Nasopharyngeal Cancer1 trial

Squamous Cell Cancer of the Head and Neck1 trial

Advanced Solid Tumors1 trial

Urothelial Cancer1 trial

Cervical Cancer1 trial

Recurrent Cancer1 trial

First Line Therapy1 trial

Cancer of Unknown Primary1 trial

Patients With Solid Tumors1 trial

Pancreatic Adenocarcinoma1 trial

Adenocarcinoma1 trial

Metastatic Colon Cancer1 trial

T-cell non-Hodgkin lymphoma1 trial

Transitional Cell Carcinoma1 trial

Triple-Negative Breast Cancer1 trial

Malignant Mesothelioma1 trial

Acute Lymphoblastic Leukemia1 trial

Relapsed or Refractory1 trial

Epithelial Tumor1 trial

Ovarian Cancer1 trial

Soft Tissue Sarcoma1 trial

Stage IV Ovarian Epithelial Cancer1 trial

Squamous Cell Cancer1 trial

Lymphoid Malignancies1 trial

HER2-Positive Solid Tumor1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News